LUND,
Sweden, Nov. 30, 2022 /PRNewswire/ -- Immunovia
(Nasdaq Stockholm: IMMNOV) today announced that the Centers for
Medicare and Medicaid Services (CMS) has finalized their payment
determination on a price of $897 for
Immunovia's IMMray PanCan-d test. The determined rate will be
effective from 1st January
2023.
After a period of public comment CMS agreed with the
recommendation made by the Clinical Diagnostic Laboratory Test
(CDLT) Advisory Panel to crosswalk IMMray PanCan-d rate to code
81503, brand name OVA1, and set a price of $897 for Immunovia's test.
"The CMS decision is a significant milestone in the
commercialization efforts for our IMMray PanCan-d test and a
further step on our path towards reimbursement. We are very pleased
with CMS determination as it reinforces the value of the IMMray
PanCan-d test. We continue to advance in our mission ensuring
patients have access to early detection testing for pancreatic
cancer in high-risk populations," said Philipp Mathieu, CEO and President of
Immunovia.
CMS is a federal agency within the United States Department of
Health and Human Services that provides health coverage to more
than 100 million people in the U.S. CMS sets the basis for payment
for lab tests through the clinical lab free schedule
(CLFS).
More information on the billing and coding decision can be found
on the CMS website under "Final Payment
Determinations".
For more information, please contact:
Philipp Mathieu,
CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information see:
www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
###
The following files are available for download:
https://mb.cision.com/Main/13121/3675195/1703988.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/centers-for-medicare--medicaid-services-finalizes-its-payment-determination-and-sets-a-rate-of-897-for-immunovias-immray-pancan-d-test-301689926.html
SOURCE Immunovia AB